Profound Therapeutics is the latest life science company to select R&D Logic!
September 2025
The team at Profound Therapeutics is making profound impacts on their understanding of biology and disease, empowering them to create therapeutics that would not have previously been possible – another step closer to making a profound impact on human health.
Adverum Biotechnologies selects R&D Time !!!!!
September 2025
Adverum is driven to establish gene therapy as a new standard of care for the leading causes of vision loss.
Oxford BioTherapeutics recognizes R&D Logic as the leader in R&D time collection software
September 2025
Oxford BioTherapeutics is dedicated to pioneering the next generation of oncology treatments through targeted therapies, including Antibody-Drug Conjugates (ADC), Immuno-oncology, T-Cell Engagers (TCE), and radiopharmaceuticals.
Monte Rosa Therapeutics is the latest life science company to recognize the value of R&D Logic’s project time collection tool, R&D Time.
March 2025
Monte Rosa Therapeutics is a biotechnology company developing molecular glues to degrade disease-causing proteins by creating a platform that designs small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable.